Abstracts tagged "Spondylarthritis"

Abstract Number: 1910 • 2019 ACR/ARP Annual Meeting
Inflammatory Processes in Experimental Spondyloarthritis Are Accompanied by Formation of Ectopic Lymphoid Structures and B Cell Lineage Alterations in the Bone Marrow
Merlijn Kaaij¹, Jan Piet van Hamburg ¹, Jasper Rip ², George Kollias ³, Leonie van Duivenvoorde ¹, Martijn Nolte ⁴, Dominique Baeten ¹ and Sander Tas ¹, ¹Amsterdam Rheumatology & immunology Center, Amsterdam UMC/University of Amsterdam, Amsterdam, Netherlands, ²Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Rotterdam, Netherlands, ³Division of Immunology, Biomedical Sciences Center ”Alexander Fleming”, Vari, Greece, Vari, Greece, ⁴Sanquin Research and Landsteiner Laboratory, Molecular & Cellular Hemostasis, Amsterdam UMC/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Tumour necrosis factor a (TNF) is important in immune-mediated inflammatory diseases such as spondyloarthritis (SpA). Transmembrane (tm)TNF-transgenic (tg) mice that overexpress tmTNF develop typical…
Abstract Number: 605 • 2019 ACR/ARP Annual Meeting
Macrophage Migration Inhibitory Factor Is a Critical Regulator in a Mouse Model of Spondyloarthritis
Akihiro Nakamura¹, Fanxing Zeng ¹, Sayaka Nakamura ¹, Richard Bucala ² and Nigil Haroon ³, ¹University Health Network, Toronto, Canada, ²Yale University School of Medicine, New Haven, CT, ³Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Spondyloarthritis (SpA) is a chronic rheumatic disease characterized by severe inflammation in the spine, peripheral joints, intestine, skin and eyes. Although current treatment modalities…
Abstract Number: 1911 • 2019 ACR/ARP Annual Meeting
Targeting the Oxidative Stress Pathway in Experimental Spondyloarthritis Reduces Pro-inflammatory Response in Rat Macrophages and Modulates Their Metabolic Requirements
Fatemeh Navid¹, Francesca LiCausi ¹, Breanna Nguyen ¹, Antony Cougnoux ², Pierre-Christian Violet ³, Mark Levine ³ and Robert Colbert ¹, ¹NIAMS/NIH, bethesda, ²NICHDR/NIH, Bethesda, ³NIDDK/NIH, Bethesda
Background/Purpose: HLA-B27 is associated with the development of spondyloarthritis (SpA) and has a tendency to generate ER stress due to misfolding which can activate the…
Abstract Number: 632 • 2019 ACR/ARP Annual Meeting
An Observational Analysis of the Co-existence of Brugada Syndrome in Patients with Spondyloarthritis; A Potentially Important Link
Kunal Lall ¹, Robbie Ramsden ², Elijah R. Behr ³ and Virinderjit Sandhu², ¹St.George's University Medical School, London, United Kingdom, ²Department of Rheumatology, St.George's Hospital NHS Foundation Trust, London, United Kingdom, ³Department of Cardiology, St.George's Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Cardiac involvement in Spondyloarthritis (SpA) has been recognised as an important determinant of increased comorbidity and mortality due to atherosclerosis, aortitis, aortic regurgitation and…
Abstract Number: 2321 • 2019 ACR/ARP Annual Meeting
Subclinical Myocardial Dysfunction Assessed by Strain Imaging in Patients with Rheumatoid Arthritis and Spondyloarthritis
Guillaume CLERFOND ¹, Marc VILLEDON DE NAIDE ², Clara ALLEMAND ³, Lucie ULMANN ³, Romain ESCHALIER ³, Martin SOUBRIER ⁴, Bruno Pereira ⁵ and Anne TOURNADRE⁶, ¹CHU de Clermont Ferrand, Clermont Ferrand, ²CHU de Clermont Ferrand, Clermont -Ferrand, France, ³CHU de Clermont Ferrand, Clermont Ferrand, France, ⁴CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, ⁵CHU CLERMONT-FERRAND, CLERMONT-FERRAND, France, ⁶CHU de Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Although cardiovascular (CV) risk and mortality are increased in rheumatoid arthritis (RA) and spondyloarthritis (SpA), mechanisms resulting in CV risk excess and stratification are…
Abstract Number: 687 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Spondyloarthritis Patients in Japan in Comparison to Other Regions of the World
Haruki Sawada¹, Kazuki Yoshida², Naomi Ichikawa³, Hisashi Inoue⁴, Yuko Kaneko⁵, Taku Kawasaki⁶, Kazuo Matsui⁷, Mitsuhiro Morita⁸, Kurisu Tada⁹, Naoho Takizawa¹⁰, Naoto Tamura⁹, Atsuo Taniguchi³, Yoshinori Taniguchi¹¹, Shigeyoshi Tsujii¹², Yoichiro Haji¹³, Masei Suda¹⁴, Haruyuki Yanaoka¹⁵, Ryo Rokutanda¹⁴, Masato Okada¹⁴, Clementina López Medina¹⁶, Anna Molto¹⁷, Maxime Dougados¹⁶, Désirée van der Heijde¹⁸, Shigeto Kobayashi¹⁹, Tetsuya Tomita²⁰ and Mitsumasa Kishimoto¹⁴, ¹Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine, Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁶Department of Orthopedic Surgery, Shiga University of Medical Science, Shiga, Japan, ⁷Department of Rheumatology, Tonan Hospital, Hokkaido, Japan, ⁸Department of Orthopedic Surgery, Fujita Health University, Aichi, Japan, ⁹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁰Department of Rheumatology, Chubu Rosai Hospital, Aichi, Japan, ¹¹Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi, Japan, ¹²Department of Orthopedics, Osaka Minami Medical Center, Osaka, Japan, ¹³Department of Rheumatology, Daido Hospital, Aichi, Japan, ¹⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ¹⁵St. Luke's International Hospital, Tokyo, Japan, ¹⁶Department of Rheumatology, Paris Descartes University, Cochin Hospital, Paris, France, ¹⁷Department of Rheumatology, Paris Descartes University, Cochin Hospital, Paris, Japan, ¹⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁹Department of Internal Medicine, Juntendo University Koshigaya Hospital, Saitama, Japan, ²⁰Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Osala, Japan
Background/Purpose: To delineateclinical characteristicsof patients with spondyloarthritis (SpA) in Japan in comparison to other areas of the world. Methods: Utilizingthe COMOSPA data, an international cross-sectional…
Abstract Number: 1613 • 2018 ACR/ARHP Annual Meeting
Dactylitis in Early Spondyloarthritis. Baseline Data from a Prospective French National Cohort
Daniel Wendling¹, Clément Prati², Alain Saraux³, Anna Molto⁴, Thao Pham⁵, Maxime Dougados⁶ and Xavier Guillot⁷, ¹Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ²Rheumatology, University Hospital - Bourgogne Franche Comté University, Besancon, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁵Rheumatology Department, Aix-Marseille University, APHM, Marseille, France, ⁶Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, ⁷PEPITE EA 4267, Bourgogne-Franche-Comté university, Besançon, France
Background/Purpose: Dactylitis is a particular feature shared across the several phenotypical forms of spondyloarthritis (SpA), part of the classification criteria. There are only few data…
Abstract Number: 1622 • 2018 ACR/ARHP Annual Meeting
ASAS Consensus on Spanish Nomenclature for Spondyloarthritis
Victoria Navarro-Compán¹, Teresa Oton-Sanchez², Estibaliz Loza³, Raquel Almodóvar González⁴, Rafael Ariza⁵, Wilson Bautista-Molano⁶, Rubén Burgos-Vargas⁷, Eduardo Collantes Estevez⁸, Eugenio De Miguel⁹, Carlos M Gonzalez¹⁰, Jordi Gratacos-Masmitja¹¹, Sebastián Ibáñez¹², Xavier Juanola¹³, José A. Maldonado-Cocco¹⁴, Anna Molto¹⁵, Juan D. Mulero¹⁶, Cesar Pacheco-Tena¹⁷, Cesar Ramos-Remus¹⁸, Jesus Sanz¹⁹, Rafael Valle-Oñate²⁰, Pedro Zarco²¹ and Helena Marzo-Ortega²², ¹Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ²InMusc. Instituto de Salud Músculo-Esquelética, Madrid, Spain, ³INMUSC, Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁴Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, ⁵Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ⁶Hospital Militar, Bogotá, Colombia, ⁷Department of Rheumatology, Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁹Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ¹⁰Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹¹Rheumatology, Hospital Parc Taulí, Sabadell - Barcelona, Spain, ¹²Rheumatology Department, Clínica Alemana de Santiago, Santiago, Chile, ¹³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Buenos Aires University, Consulting Professor of Rheumatology, Buenos Aires University. Argentina, Buenos Aires, Argentina, ¹⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ¹⁶Hospital Puerta de Hierro, Majadahonda, Madrid, Spain, ¹⁷Universidad Autónoma de Chihuahua, Hospital Christus Muguerza del Parque, Chihuahua, Mexico, ¹⁸Universidad Autonoma de Guadalajara, Zapopan, Mexico, ¹⁹Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁰Unidad de Reumatologia, Hospital Militar, Bogota, Colombia, ²¹H Fundación Alcorcón, Alcorcón, Spain, ²²NIHR LBRC, LTHT and LIRMM, UoL, Leeds, United Kingdom
Background/Purpose: In the last three decades, major advances in the spondyloarthritis (SpA) field have been achieved leading to new terminology. Whilst this terminology is well…
Abstract Number: 2574 • 2018 ACR/ARHP Annual Meeting
Tapering TNF Inhibitors in Axial Spondyloarthritis: Systematicanalysisoftheliteratureandmeta-Analysis
Loukianos Couvaras¹, Thomas Barnetche², Arnaud Constantin³ and Thao Pham⁴, ¹Rheumatology, Aix-Marseille University, APHM, Marseille, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, ⁴Rheumatology Department, Aix-Marseille University, APHM, Marseille, France
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in treating patients with axial spondyloarthritis (axSpA), but they are associated with adverse effects and high costs.…
Abstract Number: 1516 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors
M. Victoria Hernández¹, Marina Mesquida¹, Victor Llorens², Maite Sainz de la Maza², Ricardo Blanco³, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Ana Urruticoechea-Arana⁷, Juan Ramon De Dios⁸, Pilar Ahijado-Guzman⁹, Enrique Judez¹⁰, Patricia Tejón¹¹, M Soledad Peña¹², Francisca Sivera¹³, Alfredo Adan¹ and Raimon Sanmarti¹⁴, ¹Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla., Santander, Spain, ⁵Hospital Donostia. Spain, San Sebastian, Spain, ⁶Ophthalmology Department. Hospital Donostia, San Sebastian, Spain, ⁷Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁸Rheumatology Department. Hospital Universitario de Araba, Vitoria, Spain, ⁹Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ¹⁰Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹¹Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophtalmology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹³Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain, ¹⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Uveitis is a common extra-articular manifestation in patients with spondyloarthritis (SpA) requiring, in most severe cases, the use of biological therapy, especially tumour necrosis…
Abstract Number: 1535 • 2017 ACR/ARHP Annual Meeting
Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment
Mireia Moreno¹, Caridad Pontes², Ferran Torres³, Agusti Sellas-Fernandez⁴, Miriam Almirall⁵, Juan Carlos Torre-Alonso⁶, Teresa Clavaguera⁷, Carlos Rodriguez-Lozano⁸, Luis Francisco Linares⁹, Ana Urruticoechea-Arana¹⁰, Eduardo Collantes-Estevez¹¹, Rosa Morla¹², Delia Reina¹³, Eduardo Cuende¹⁴, Pedro Zarco¹⁵, Cruz Fernandez-Espartero¹⁶, Rosario García-Vicuña¹⁷, Jesus Sanz¹⁸, Xavier Juanola¹⁹, Antoni Vallano²⁰, Francisco J Blanco²¹, Raimon Sanmarti²², Gonzalo Calvo²³, Cristina Avendaño²⁴, Eugenio De Miguel²⁵, Roser Vives²⁶, Raul Veroz Gonzalez²⁷, Carlos Alberto Montilla-Morales²⁸ and Jordi Gratacos-Masmitja²⁹, ¹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, ²Clinic Pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ³Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁵Rheumatology, Hospital del Mar, Barcelona, Spain, ⁶H Monte Naranco, Oviedo, Spain, ⁷Rheumatology. Palamós Hospital, Rheumatologist, Catalonia, Spain, ⁸Rheumatology, Hospital Universitario Dr. Negrin, Gran Canaria, Spain, ⁹Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹⁰Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ¹¹Rheumatology, IMIBIC-Hospital Universitario Reina Sofia, Cordoba, Spain, ¹²Rambla Vella, 14, Hospital La Tecla, Tarragona, Spain, ¹³Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁴University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹⁵H Fundación Alcorcón, Alcorcón, Spain, ¹⁶Rheumatology, Hospital de Mostoles, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁸Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁰Clinic pharmacology, Hospital Universitari Bellvitge, Barcelona, Spain, ²¹Servicio de Reumatología. Area Genomica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ²²Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ²³Clinic pharmacology, Hospital Clinic Barcelona, Barcelona, Spain, ²⁴Clinic pharmacology, Hospital Puerta de Hierro, Madrid, Spain, ²⁵Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²⁶Clinic pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ²⁷Hospital de Mérida, Mérida, Spain, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²⁹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Barcelona, Spain
Background/Purpose: Some clinical guidance recommends empirical TNFi dose reductions in AS patients despite lack of robust supportive evidence. Recently, we communicated that a strategy of…
Abstract Number: 2801 • 2017 ACR/ARHP Annual Meeting
Effects of Anti-IL17 Blockade with Secukinumab on Systemic and Local Immune Responses: A Mechanism-of-Action Study in Peripheral Spondyloarthritis
Leonieke van Mens¹, Marleen van de Sande², Silvia Menegatti³, Iris Blijdorp¹, Jet de Jong², Inka Fluri⁴, Talia Latuhihin¹, Arno van Kuijk⁵, Nataliya Yeremenko⁴ and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Immunology, Immunoregulation Unit, Institut Pasteur, Paris, France, ⁴Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ⁵Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: IL-17A blockade is an effective therapy for AS and PsA, the prototypical forms of spondyloarthritis(SpA). How IL-17A blockade affects the systemic and local immune…
Abstract Number: 2821 • 2017 ACR/ARHP Annual Meeting
A Multidisciplinary Telemedicine Program for Identification of Spondyloarthritis in Medically Underserviced Communities
Christopher Hawke¹, Laura Passalent¹, Nigil Haroon², Robert D Inman³ and Y. Raja Rampersaud⁴, ¹Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ³Department of Immunology, University of Toronto, Toronto, ON, Canada, ⁴Arthritis Program, Krembil Research Institute, University Health Network, Torotno, ON, Canada
Background/Purpose: Early diagnosis is critical for optimal management of patients with inflammatory arthritis. Axial spondyloarthritis (AxSpA) has the longest delay in diagnosis among inflammatory joint…
Abstract Number: 711 • 2016 ACR/ARHP Annual Meeting
The Diagnostic Value of the Symptom of Inflammatory Back Pain in the Rheumatology Setting
Denis Poddubnyy¹, Inge Spiller¹, Joachim Listing², Jürgen Braun³, Joachim Sieper¹ and Martin Rudwaleit⁴, ¹Charité Medical University, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany
Background/Purpose: Inflammatory back pain (IBP) as a symptom has been shown to perform effectively for selecting patients in primary care / orthopaedic settings for referral…
Abstract Number: 723 • 2016 ACR/ARHP Annual Meeting
Hip Disease Treatment and Progression in Ankylosing Spondylitis
Daphne Scaramangas-Plumley¹, MinJae Lee², Mohammad H. Rahbar², Lianne S. Gensler³, John D. Reveille⁴ and Michael Weisman¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ³Medicine/Rheumatology, UCSF, San Francisco, CA, ⁴Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Methods: We included 613 AS patients meeting the modified New York criteria and had at least 2 sets of hip radiographs. Using the Bath Ankylosing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].